RNA, Technology and IP Attorneys
With the India IP office headquarters moving from Mumbai to Delhi, forum shoppers and firms in the capital could benefit
Sponsored
Sponsored
-
Sponsored by RNA, Technology and IP AttorneysRanjan Narula and Mohandas Konnanath of RNA, Technology and IP Attorneys look at Britannia and ITC’s arguments in the case which alleges conscious copying -
Sponsored by RNA, Technology and IP AttorneysRanjan Narula and Rajiv Suri of RNA, Technology and IP Attorneys consider a Supreme Court ruling where income from a software sale by non-resident companies to resident is not a ‘royalty’ payment
-
Sponsored by RNA, Technology and IP AttorneysRanjan Narula and Rajiv Suri of RNA, Technology and IP Attorneys outline how the Advertising Standards Council of India have reacted to increased online gaming trends during the COVID-19 pandemic
-
Sponsored by RNA, Technology and IP AttorneysRanjan Narula and Daleep Kumar of RNA, Technology and IP Attorneys explain how the Advertising Standards Council of India is acting to prevent misleading claims about coronavirus cures and remedies
-
Sponsored by RNA, Technology and IP AttorneysThe Working Statement which patentees need to file every year continues to be a controversial subject. The frequent changes in the forms and varying stands of the patent office have added to the confusion.
-
Sponsored by RNA, Technology and IP AttorneysCoronil, an ayurvedic drug (formulation of herbs and minerals) developed by Patanjali Ayurved that was initially promoted as a cure for the COVID-19 virus and later approved to be sold as an immunity booster to fight Coronavirus, has run into a controversy. A Chennai-based company Arudra Engineering (Arudra) filed a suit before the Madras High Court, alleging trademark infringement. Arudra sought an injunction restraining Patanjali Ayurved (Patanjali) and Divya Yog Mandir Trust, subsequently impleaded as a defendant, from using the mark "Coronil" or any deceptive variation.
